Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $1.6 billion.

  • Ascendis Pharma A's Total Liabilities rose 1875.84% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 1875.84%. This contributed to the annual value of $1.4 billion for FY2024, which is 3310.67% up from last year.
  • Per Ascendis Pharma A's latest filing, its Total Liabilities stood at $1.6 billion for Q3 2025, which was up 1875.84% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Total Liabilities ranged from a high of $1.6 billion in Q3 2025 and a low of $196.0 million during Q1 2021
  • Moreover, its 5-year median value for Total Liabilities was $857.7 million (2023), whereas its average is $902.7 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 30336.13% in 2022, then soared by 772.57% in 2023.
  • Over the past 5 years, Ascendis Pharma A's Total Liabilities (Quarter) stood at $230.3 million in 2021, then surged by 266.15% to $843.1 million in 2022, then increased by 23.95% to $1.0 billion in 2023, then skyrocketed by 31.42% to $1.4 billion in 2024, then increased by 13.11% to $1.6 billion in 2025.
  • Its Total Liabilities was $1.6 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.3 billion in Q1 2025.